Protalix BioTherapeutics, Inc.PLXEarnings & Financial Report
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Revenue
$10.5M
Gross Profit
$1.6M
Operating Profit
$-5.6M
Net Profit
$-6.0M
Gross Margin
15.5%
Operating Margin
-53.5%
Net Margin
-57.6%
YoY Growth
21.7%
EPS
$-0.03
Protalix BioTherapeutics, Inc. Q4 FY2023 Financial Summary
Protalix BioTherapeutics, Inc. reported revenue of $10.5M (up 21.7% YoY) for Q4 FY2023, with a net profit of $-6.0M (down 61.6% YoY) (-57.6% margin). Cost of goods sold was $8.9M, operating expenses totaled $7.2M.
Key Financial Metrics
| Total Revenue | $10.5M |
|---|---|
| Net Profit | $-6.0M |
| Gross Margin | 15.5% |
| Operating Margin | -53.5% |
| Report Period | Q4 FY2023 |
Protalix BioTherapeutics, Inc. Annual Revenue by Year
Protalix BioTherapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $52.7M).
| Year | Annual Revenue |
|---|---|
| 2025 | $52.7M |
| 2023 | $65.5M |
| 2022 | $47.6M |
Protalix BioTherapeutics, Inc. Quarterly Revenue & Net Profit History
Protalix BioTherapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $9.1M | -49.9% | $-5.5M | -60.3% |
| Q3 FY2025 | $17.9M | -0.6% | $2.4M | 13.2% |
| Q2 FY2025 | $15.7M | +16.2% | $164.0K | 1.0% |
| Q1 FY2025 | $10.1M | +169.8% | $-3.6M | -35.8% |
| Q4 FY2024 | $18.2M | +73.7% | $6.5M | 35.6% |
| Q3 FY2024 | $18.0M | +73.6% | $3.2M | 18.0% |
| Q2 FY2024 | $13.5M | -61.6% | $-2.2M | -16.4% |
| Q4 FY2023 | $10.5M | +21.7% | $-6.0M | -57.6% |
Income Statement
| Q4 2023 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.5M | $13.5M | $18.0M | $18.2M | $10.1M | $15.7M | $17.9M | $9.1M |
| YoY Growth | 21.7% | -61.6% | 73.6% | 73.7% | 169.8% | 16.2% | -0.6% | -49.9% |
Balance Sheet
| Q4 2023 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $84.4M | $91.5M | $61.6M | $73.4M | $73.9M | $78.5M | $82.3M | $82.3M |
| Liabilities | $50.9M | $63.0M | $29.1M | $30.2M | $28.7M | $28.6M | $29.4M | $34.1M |
| Equity | $33.6M | $28.6M | $32.4M | $43.2M | $45.2M | $49.9M | $52.9M | $48.2M |
Cash Flow
| Q4 2023 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $3.6M | $-3.6M | $4.1M | $4.0M | $-5.1M | $-5.2M | $-3.7M | $2.0M |